Partnering / Current Partnerships
Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced on April 10, 2018 the acquisition of Baliopharm AG (click here to read the press release). The transaction complements Promethera’s pipeline with the anti-TNF-R1 specific antibodies Atrosab and Atrosimab. Combining this novel therapeutic strategy with Promethera’s unique liver cell-based therapies could provide improved treatment option for patients suffering from Nonalcoholic steatohepatitis (NASH) and potentially other severe liver diseases.
Baliopharm maintains a long-term partnership with the Institute of Cell Biology and Immunology at the University of Stuttgart, who support the early R&D and preclinical development activities of Atrosab and Atrosimab with deep scientific expertise of cytokine-based therapeutics.